To the full analysis
Celldex Therapeutics stock: growth
CLDXCelldex Therapeutics reported $1.5M in revenue for fiscal 2025, down 78.6% on the prior year, down 27.4% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
−6.1%
per year from 2006 to 2025, per share −28.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −27.4% | −12.2% | −6.1% |
| Revenue per share | −38.2% | −30.4% | −28.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $4.93M | −$20.37M | $17.68M |
| 2007 | $5.1M | −$21.64M | −$24.28M |
| 2008 | $7.46M | −$47.5M | $16.98M |
| 2009 | $15.18M | −$36.53M | −$30.4M |
| 2010 | $46.79M | −$2.53M | −$32.47M |
| 2011 | $9.27M | −$44.8M | −$36.17M |
| 2012 | $11.2M | −$59.12M | −$50.09M |
| 2013 | $4.11M | −$81.55M | −$71.89M |
| 2014 | $3.59M | −$118.08M | −$103.47M |
| 2015 | $5.48M | −$127.2M | −$103.76M |
| 2016 | $6.79M | −$128.53M | −$115.79M |
| 2017 | $12.74M | −$93.03M | −$101.72M |
| 2018 | $9.54M | −$151.18M | −$76.05M |
| 2019 | $3.57M | −$50.88M | −$47.15M |
| 2020 | $7.42M | −$59.78M | −$41.96M |
| 2021 | $4.65M | −$70.51M | −$62.16M |
| 2022 | $2.36M | −$112.33M | −$105.56M |
| 2023 | $6.88M | −$141.43M | −$109.11M |
| 2024 | $7.02M | −$157.86M | −$159.7M |
| 2025 | $1.5M | −$258.8M | −$213.66M |
Revenue by segment
How Celldex Therapeutics, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Grant97%
- Service6%
Figures as a table
| 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|
| Grant | $2.3M | $6.61M | $7.01M | $1.45M | 96.5% |
| Service | $56K | $278K | $13K | $97K | 6.5% |
| Total revenue | $2.36M | $6.88M | $7.02M | $1.5M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Oct 2006)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.